{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:06:34Z","timestamp":1775243194622,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,8,24]],"date-time":"2011-08-24T00:00:00Z","timestamp":1314144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00535-011-0446-2","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T18:34:36Z","timestamp":1314124476000},"page":"1273-1283","source":"Crossref","is-referenced-by-count":42,"title":["Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs\u2014TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan"],"prefix":"10.1007","volume":"46","author":[{"name":"The Acid-Related Symptom Research Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Furuta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Shimatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsushige","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyasu","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,24]]},"reference":[{"issue":"5","key":"446_CR1","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1023\/A:1018822532736","volume":"43","author":"ML Cloud","year":"1998","unstructured":"Cloud ML, Enas N, Humphries TJ, Bassion S. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci. 1998;43(5):993\u20131000.","journal-title":"Dig Dis Sci"},{"key":"446_CR2","doi-asserted-by":"crossref","unstructured":"Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16(3):445\u201354 (Erratum in: Aliment Pharmacol Ther. 2002;16(5):1035).","DOI":"10.1046\/j.1365-2036.2002.01181.x"},{"issue":"6","key":"446_CR3","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","volume":"97","author":"P Miner Jr","year":"2002","unstructured":"Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97(6):1332\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"446_CR4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2036.2007.03350.x","volume":"26","author":"H Miwa","year":"2007","unstructured":"Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007;26(1):69\u201377.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"446_CR5","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1440-1746.2007.05218.x","volume":"23","author":"M Miyamoto","year":"2008","unstructured":"Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008;23(5):746\u201351.","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"446_CR6","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/ajg.2009.50","volume":"104","author":"R Fass","year":"2009","unstructured":"Fass R. Proton pump inhibitor failure\u2014what are the therapeutic options? Am J Gastroenterol. 2009;104(Suppl 2):S33\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"446_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/MEG.0b013e3282f1cc39","volume":"20","author":"AJ Bredenoord","year":"2008","unstructured":"Bredenoord AJ, Smout AJ. Refractory gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol. 2008;20(3):217\u201323.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"446_CR8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MOG.0b013e32833ae2be","volume":"26","author":"T Hershcovici","year":"2010","unstructured":"Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol. 2010;26(4):367\u201378.","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"446_CR9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00535-006-1775-4","volume":"41","author":"M Hongo","year":"2006","unstructured":"Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol. 2006;41(2):95\u20139.","journal-title":"J Gastroenterol"},{"issue":"9","key":"446_CR10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00535-008-2214-5","volume":"43","author":"N Uemura","year":"2008","unstructured":"Uemura N, Inokuchi H, Serizawa H, Chikama T, Yamauchi M, Tsuru T, et al. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol. 2008;43(9):670\u20138.","journal-title":"J Gastroenterol"},{"issue":"Suppl 2","key":"446_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2036.2005.02468.x","volume":"21","author":"Y Fujiwara","year":"2005","unstructured":"Fujiwara Y, Higuchi K, Nebiki H, Chono S, Uno H, Kitada K, et al. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;21(Suppl 2):10\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"446_CR12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1067\/mcp.2002.127637","volume":"72","author":"T Furuta","year":"2002","unstructured":"Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002;72(4):453\u201360.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"446_CR13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/phgs.5.2.181.27483","volume":"5","author":"T Furuta","year":"2004","unstructured":"Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181\u2013202.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"446_CR14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2133\/dmpk.20.153","volume":"20","author":"T Furuta","year":"2005","unstructured":"Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153\u201367.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"9","key":"446_CR15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00535-004-1417-7","volume":"39","author":"M Kusano","year":"2004","unstructured":"Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39(9):888\u201391.","journal-title":"J Gastroenterol"},{"issue":"7","key":"446_CR16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s10620-006-9674-3","volume":"52","author":"M Kusano","year":"2007","unstructured":"Kusano M, Shimoyama Y, Kawamura O, Maeda M, Kuribayashi S, Nagoshi A, et al. Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. Dig Dis Sci. 2007;52(7):1673\u20137.","journal-title":"Dig Dis Sci"},{"issue":"3 Suppl","key":"446_CR17","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0002-9270(03)00013-3","volume":"98","author":"P Bytzer","year":"2003","unstructured":"Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol. 2003;98(3 Suppl):S31\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"446_CR18","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1046\/j.1365-2036.2000.00829.x","volume":"14","author":"JG Hatlebakk","year":"2000","unstructured":"Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267\u201372.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"446_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1365-2036.2003.01821.x","volume":"19","author":"T Shimatani","year":"2004","unstructured":"Shimatani T, Inoue M, Kuroiwa T, Horikawa Y. Rabeprazole 10\u00a0mg twice daily is superior to 20\u00a0mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther. 2004;19(1):113\u201322.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"446_CR20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.dld.2006.06.002","volume":"38","author":"T Shimatani","year":"2006","unstructured":"Shimatani T, Moriwaki M, Xu J, Tazuma S, Inoue M. Acid-suppressive effects of rabeprazole: comparing 10\u00a0mg and 20\u00a0mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Dig Liver Dis. 2006;38(11):802\u20138.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"446_CR21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","volume":"2","author":"BB Dean","year":"2004","unstructured":"Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2(8):656\u201364.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"446_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1442-2050.2002.00261.x","volume":"15","author":"T Kamolz","year":"2002","unstructured":"Kamolz T, Velanovich V. Psychological and emotional aspects of gastroesophageal reflux disease. Dis Esophagus. 2002;15(3):199\u2013203.","journal-title":"Dis Esophagus"},{"issue":"5","key":"446_CR23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2036.2002.01248.x","volume":"16","author":"M Frazzoni","year":"2002","unstructured":"Frazzoni M, De Micheli E, Grisendi A, Savarino V. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther. 2002;16(5):881\u20136.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"446_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0016-5085(99)70544-5","volume":"117","author":"G Holtmann","year":"1999","unstructured":"Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology. 1999;117(1):11\u20136.","journal-title":"Gastroenterology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-011-0446-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-011-0446-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-011-0446-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T09:04:24Z","timestamp":1560503064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-011-0446-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,24]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s00535-011-0446-2","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,24]]}}}